Xenon Pharmaceuticals Inc (XENE) — Cash Flow-to-Debt Ratio
Xenon Pharmaceuticals Inc (XENE) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of $-81.48 Million could theoretically repay 0% of its total liabilities ($399.91 Million) in one year. See how much free cash does Xenon Pharmaceuticals Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Xenon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Xenon Pharmaceuticals Inc across 14 annual periods. Also explore XENE year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Xenon Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Xenon Pharmaceuticals Inc. For market capitalisation and broader financial context, see Xenon Pharmaceuticals Inc (XENE) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-279.12 Million | $399.91 Million | ▲ +83.4% |
| 2024 | -4.20x | $-181.39 Million | $43.24 Million | ▼ -6.5% |
| 2023 | -3.94x | $-145.33 Million | $36.88 Million | ▼ -30.7% |
| 2022 | -3.01x | $-98.43 Million | $32.65 Million | ▲ +4.7% |
| 2021 | -3.16x | $-69.50 Million | $21.97 Million | ▼ -17.2% |
| 2020 | -2.70x | $-48.12 Million | $17.83 Million | ▼ -3146.6% |
| 2019 | -0.08x | $-4.63 Million | $55.72 Million | ▲ +95.4% |
| 2018 | -1.81x | $-34.72 Million | $19.13 Million | ▲ +35.6% |
| 2017 | -2.82x | $-28.73 Million | $10.19 Million | ▲ +48.3% |
| 2016 | -5.46x | $-19.57 Million | $3.59 Million | ▲ +12.1% |
| 2015 | -6.21x | $-18.10 Million | $2.92 Million | ▼ -34277.6% |
| 2014 | 0.02x | $266.00K | $14.64 Million | ▲ +116.6% |
| 2013 | -0.11x | $-3.32 Million | $30.37 Million | ▼ -112.2% |
| 2012 | 0.90x | $45.57 Million | $50.68 Million | — |